NT5E and cancer: Indeed, CD73 is considered an appealing therapeutic target for treating cancer and the CD73 inhibitor α, β-methylene adenosine 5′-diphosphate (APCP) shows promising anticancer activity, by inhibiting CD73-mediated functions in tumor cells and in T-cell immunity [33, 36, 37].